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Received 3 September 2007; received in revised form 7 November 2007; accepted 13 November 2007; Available online 20 December 2007AbstractBackground: Increasing age and comorbidities among patients undergoing coronary artery bypass surgery (CABG) stimulates the exhaustive
research for alternative grafts. No-ReactW treatment should render the tissue resistant against degeneration and reduce early inflammatory
response. The aim of the present study was an invasive assessment of the patency of No-ReactW bovine internal mammary artery (NRIMA grafts)
used as bypass conduit in CABG surgery. Patients andmethods:NineteenNRIMA grafts were used in 17 patients (2.9%) out of a total of 572 patients
undergoing CABG surgery within a 12-month period. All intraoperative data were assessed and in-hospital outcome was analysed. Follow-up
examination was performed 7.0  4.0 months after initial surgery, including clinical status and coronary angiography to assess patency of the
NRIMA grafts. Results: Average perioperative flow of all NRIMA grafts was 71  60 ml/min. One patient died in hospital due to a multi-organ
failure. Four patients refused invasive assessment. Follow-up was complete in 12 patients with overall 13 NRIMA grafts. Nine NRIMA grafts (69.2%)
were used for the right coronary system, two NRIMA grafts (15.4%) on the LAD and two on the circumflex artery. Graft patency was 23.1% and was
independent of the intraoperative flow measurement. Conclusions: NRIMA grafts show a very low patency and cannot be recommended as
coronary bypass graft conduits. Patency was independent of the perioperative flow, assessed by Doppler ultrasound. Because of this unsatisfying
observation, this type of graft should be utilised as a last resource conduit and used only to revascularise less important target vessels, such as the
end branches of the right coronary artery.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Patients undergoing coronary artery bypass surgery
(CABG) currently present with an increasing age and risk-
profile. In older patients quality of saphenous vein grafts may
be impaired. Therefore, alternative bypass conduits are
always welcome. Arterial grafts (such as bilateral internal
thoracic artery and radial artery) represent the best option,
however harvesting is more demanding and the availability is
limited. Previous attempts with xenografts and synthetic
conduits in CABG surgery were not successful. No-React
treatment is a proprietary technique established by Shelhigh,
Inc., Union, NJ, USA: there is increasing evidence of its ability
to resist in vivo and in vitro calcification. However, these
findings are discussed controversially [1—3].
No-React bovine internal mammary artery (NRIMA)
conduit for CABG surgery has been available for restricted§ Presented at the 21st Annual Meeting of the European Association for
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been published in the literature so far [4]. The manufacturer
underlines that the indication and the use of this product are
the responsibilities of the treating physician and that patency
of NRIMA as coronary graft is around 60—80% and therefore
less favourable than the patency observed with the same
conduit in peripheral vascular disease. Shelhigh recommends
the use of anticoagulation, antiaggregants or a combination
of the two, for the first 3 months following surgery and
salicylic acid once daily as life-long prophylaxis. The aim of
the present study was the invasive assessment of patency of
No-ReactW bovine internal mammary artery (NRIMA grafts)
following CABG surgery.2. Patients and methods
Five hundred and seventy two patients underwent CABG
surgery during a 12-month period at our institution. In 17
patients (2.9%) an NRIMA graft was implanted due to
unavailable autologous graft material. All in-hospital data
of these patients were analysed, especially the surgicalurgery. Published by Elsevier B.V. All rights reserved.
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as bypass graft, its diameter and the flow measured in the
graft at the end of surgery. Transit-time flow was measured
with the Medi-Stim Butterfly Flowmeter (Medi-Stim AS, Oslo,
Norway). An invasive follow-up was performed in all patients
7.0  4.0 months after surgery. One patient died in hospital
due to a multi-organ failure, 4 patients refused an invasive
follow-up and 12 patients (70.6%) underwent coronary
angiography. Patient characteristics are summarized in
Table 1. All patients received oral anticoagulants for at
least 3 months following surgery combined with salicylic acid
and 100 mg salicylic acid thereafter according to the
instructions of the manufacturer.3. Results
The mean age of the 17 patients was 73.0  4.4 years and
41.8% were male gender. Patients presented with the usual
cardiovascular risk factors encountered in CABG surgery
population (arterial hypertension 88.2%, diabetes mellitus
29.4%, history of smoking 41.2% and cholesterol 52.9%).
Average EuroScore was 7.0  3.4. Average number of distal
anastomoses was 3.4  0.9. Internal thoracic artery was used
in 16 patients, in 12 of them bilateral. The reasons for using
NRIMA graftswere related to the poor quality of the saphenous
vein in 16 patients (94.1%) and in 8 patients (47.1%) harvesting
of the radial artery was not possible due to a pathological
Allen’s test. In 17 patients, a total of 19 NRIMA grafts were
implanted. Eleven grafts (57.3%) were used for the right
coronary artery (RCA) out of which five (26.3%) were
anastomosed to the end branches of the right coronary
system, four grafts (21.1%) were used for the left anterior
descending artery (LAD) or its side branches and the remainingTable 1
Patients’ characteristics (n = 17)
Number of patients 17 100.0%
Mean age (years) 73.0  4.4
Male gender 7 41.2%
Height (cm) 166.0  7.2
Weight (kg) 76.0  16.1
Risk factors
Arterial hypertension 15 88.2%
Diabetes 5 29.4%
Cholesterol 5 52.9%
History of smoking 7 41.2%
EuroScore 7.0  3.4
Intraoperative data
Combined surgery 10 58.8%
AVR 9
AVR and Asc Aorta 1
ECC-time (min) 104.3  43.3
ACC-time (min) 65.2  30.0
Postoperative data
Myocardial infarction 1 5.9%
Atrial fibrillation 2 11.8%
Length of stay (days) 14.3  14.8
Results displayed as absolute values or average value  first standard devia-
tion. AVR = aortic valve replacement; AVR and Asc Aorta = aortic valve repla-
cement and ascending aorta replacement; ECC-time = extracorporeal
circulation time; ACC-time 0 aortic dross-clamping time.four grafts (21.1%) were anastomosed to the circumflex artery
(RCX). In four patients (21.1%) the NRIMA was used as a
sequential bypass. Average distal diameter of the NRIMA was
3.0  1.3 mm. The intraoperative flow, assessed by Doppler
ultrasound, was 71.0  59.5 ml/min. The flow was 100.0 
90.1 ml/min for the RCA, 40.0  15.8 ml/min for the end
branches of the RCA, 87.0  40.4 ml/min for the LAD and
55.0  20.8 ml/min for the RCX. There was no difference
looking at the quality and the diameter of the target vessel at
the site of the distal anastomoses. Good quality of the target
vessel was reported in nearly 50% of the sites of the distal
anastomoses in all three vessels and the diameter of the LAD
was slightly higher, compared to thediameter reported for RCX
and RCA. There were no significant differences between
quality and diameter in vessels grafted with NRIMA or with the
internal thoracic artery, respectively, saphenous vein grafts.
Twelve patients accepted an invasive assessment with
coronary angiography after a mean follow-up period of 7  4
months: a total of 13 NRIMA grafts were assessed (Table 2).
Four grafts (30.8%) on the RCA, five (38.5%) on the end
branches of the RCA, two (15.4%) were anastomosed to the
LAD and two on the RCX. Three out of 13 NRIMA grafts were
patent (23.1%): one NRIMA graft anastomosed to the LAD and
two grafts anastomosed to the end branches of the RCA. Eight
patients (66.7%) were asymptomatic at the time of follow-
up. The remaining four patients suffered from unspecific
symptoms. Patency of the internal thoracic artery was 100%
(nine left internal thoracic artery and six right thoracic
artery) and patency of saphenous vein graft was 94% (15 out
of 16 vein grafts were patented).4. Discussion
Alternative conduits in CABG surgery may be welcome. An
off-shelf graft of good quality would allow reducing the
incidence of postoperative problems at the site of harvesting
and facilitating surgical procedure. However, previous
attempts with xenografts and synthetic conduits in CABG
surgery were not successful and autografts are not routinely
available. The No-React bovine internal mammary artery is
described by the company as a valuable alternative with an
acceptable patency rate in the animal model. Preliminary
clinical results revealed a patency rate of 57% at a follow-upTable 2
Follow-up data
Number of patients 17 100.0%
Follow-up mortality 1 5.9%
Refused PCI 4 23.5%
Follow-up completed 12 70.6%
Average follow-up (m) 7.0  4.0
Number of NRIMA 13 100.0%
RCA end branches 4
RCA end branches 5
LAD 2
Circumflex artery 2
Patency at follow-up
Overall 3 23.1%
LAD 1
RCA end branches 2
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small collective of six patients revascularised with seven
NRIMA grafts [4].
In our experience alternative grafts are usually required in
less than 3% of the patients undergoing CABG surgery. The
widespread use of the radial artery as arterial graft in our
institution helps to solve these problems when the quality of
saphenous vein was not sufficient enough. In our collective
the NRIMAwas anastomosed to the RCA in the majority of the
patients. Average intraoperative flow (71.0  59.5 ml/min)
was slightly higher from the average flow usually measured in
conventional grafts [5]. However, graft patency was inde-
pendent of the intraoperative flow measurement. Two out of
three grafts (23.1%) anastomosed to the end branches of the
right coronary system were patent follow-up but had a
significantly lower intraoperative flow that observed in the
overall collective (40  16 ml/min in comparison to the
average flow of 71.0  59.5 ml/min in the total collective).
This observation is not congruent with the findings described
in the literature for autologous grafts where patency is
superior in high-flow grafts [6]. One explanation for the
finding that low-flow NRIMA grafts have a better mid-term
patency than high-flow grafts may be the observation
described from Ostapczuk et al. [7] in the calf model, where
a chronic rejection of the NRIMA was observed.
In other Shelhigh No-React treated implants, for instance
the porcine pulmonic valve conduit, Schreiber et al. [8] found
that these valves are largely resistant to calcification.
However, pseudointimal peel formation was found in all
explanted valves, which finally led to multilevel conduit
stenoses [8]. Poor experiences have also been described by
another group using a porcine internal mammary artery in a
calf model. In an observation period of 103 days one calf died
due to an acute thrombosis of the graft and in the remaining
four calves the porcine internal mammary artery was
occluded due to multiple calcifications and a severe chronic
rejection (host—graft immunological response) [7]. An in vivo
evaluation of the No-React bovine internal mammary artery
in a sheep-model revealed a progressive increase of
calcification within 3—6 months with minimal inflammatory
changes and preservation of the inner surface and ultra-
structure [9].
Further advances in tissue engineering will hopefully
provide us with a valuable bypass conduit alternative in
cardiac surgery in the near future. There are some promising
reports about endothelial cell-seeded bovine internal
mammary artery which could be an alternative in the future
[10].
NRIMA grafts have a very low patency and cannot be
recommended as bypass conduit for coronary surgery. Mid-
term patency is unpredictable and independent from theintraoperative flow. As a last resource bypass conduit, this
graft may be used only for less important target vessels, such
as the end branches of the right coronary artery.
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Appendix A. Conference discussion
Dr M. Grimm (Vienna, Austria): May I ask you two questions? The one is I do
fully agree with you that this is not a graft we should use. Anyhow, you
recommend this for the small vessels as an alternative graft, which I think the
smaller the vessel, the higher the risk this graft will occlude.
The second question: When using it, do you think you can overcome it by
very aggressive antiplatelet therapy?
Dr Englberger: According to the first question, there is in our small patient
cohort also a bit of a bias compared to the native grafts. We tried to avoid
placing this alternative graft in really main vessels. However, we had to do it in
two LAD grafts, and one was occluded afterwards.
To your second question: we did an oral anticoagulation for 3 months in
these patients. This is the recommendation which is given by the company
followed then by regular antiplatelet therapy with aspirin. I cannot say if more
aggressive antiplatelet therapy, maybe a combination of aspirin and
clopidogrel, will overcome this problem.
